BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals (NASDAQ: NPSP), a specialty pharmaceutical company focused on developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that patient enrollment has begun in a Phase 3 registrational study to confirm previously reported data that demonstrated GATTEX™ (teduglutide) was well tolerated and reduced parenteral nutrition (PN) dependence in short-bowl syndrome (SBS) patients. The international, double-blind, placebo-controlled safety and efficacy study of GATTEX is known as STEPS (Study of TEduglutide in PN-dependent Short-bowel syndrome). SBS is primarily caused by intestinal resection and the subsequent inability to maintain oral fluid, electrolyte, and nutrient balances.
